Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions

Australasian Radiology

Volumn 45, Issue 4, 2001, Pages 457-463

  Greco, Alina ^a   Parker, John R ^b   Ratcliffe, C George ^c   Kirchin, Miles A ^c   McNamara, Michael T ^a  

^a CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^b Bracco Research USA   (United States)

^c Bracco Imaging SpA   (Italy)

Author keywords

Central nervous system; Contrast agents; Gadopentetate dimeglumine; Gadoteridol

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL;

ADULT; AGED; ARTICLE; BRAIN INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; URTICARIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CONTRAST MEDIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS;

EID: 0035740377     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1673.2001.00957.x     Document Type: Article

References (18)

1. Clinical safety and efficacy of gadoteridol: A study in 411 subjects with suspected intracranial and spinal disease
2. Phase III clinical studies with gadoteridol for the evaluation of neurologic pathology: A European perspective
3. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases
4. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease
5. Patterns of contrast enhancement in the pediatric spine at MR imaging with single- and triple-dose gadolinium
6. Multicenter trial of gadoteridol, a nonionic gadolinium chelate, in subjects with suspected head and neck pathology
7. MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol
8. MRI evaluation of 'solitary' brain metastases with triple-dose gadoteridol: Comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI in the same subjects
9. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials
10. Safety of gadolinium-DTPA: Extended clinical experience
11. Note for Guidance Good Clinical Practice for Trials on Medicinal Products in the European Community
12. Safety of gadoteridol injection: U.S. clinical trial experience
13. Worldwide clinical safety assessment of gadoteridol injection: An update
14. Dosage of gadoteridol and adverse reactions relative to gadopentetate
15. Safety of magnetic resonance imaging contrast agents